NasdaqGS:ARQTBiotechs
Is It Too Late To Consider Arcutis Biotherapeutics (ARQT) After Its Strong 1-Year Surge?
Investors may be wondering if Arcutis Biotherapeutics at around US$26.98 is still offering value after its recent run, or if most of the opportunity is already priced in.
The stock has returned 1.4% over the last 7 days and 3.0% over the last 30 days, with a 121.1% return over 1 year and a 66.7% return over 3 years. Over the same time, the year-to-date return stands at a 7.0% decline, and the 5-year return is a 23.0% decline.
Recent headlines around Arcutis Biotherapeutics have focused on...